Zynex (NASDAQ:ZYXI) announced it has submitted a 510(k) application to the FDA for its NiCO Noninvasive CO-Oximeter device. The company stated that the submission marks a historic milestone in the evolution of pulse...
Piper Sandler launched coverage of Zynex (NASDAQ:ZYXI) with an “overweight” rating and $30 price target. The stock closed at $21.42 on July 17. Zynex sells the only three-in-one, at home, chronic pain management product...